Cowen & Co. Initiates Coverage On TESARO Inc to Market Perform

Cowen & Co. Initiates Coverage On TESARO Inc(TSRO). The shares have been rated Market Perform. The rating by Cowen & Co. was issued on Feb 6, 2017.

TESARO Inc (TSRO) made into the market gainers list on Tuesdays trading session with the shares advancing 0.77% or 1.24 points. Due to strong positive momentum, the stock ended at $162.95, which is also near the day’s high of $164.27. The stock began the session at $162.65 and the volume stood at 4,64,337 shares. The 52-week high of the shares is $164.99 and the 52 week low is $29.51. The company has a current market capitalization of $8,704 M and it has 5,34,12,407 shares in outstanding.

TESARO Inc(TSRO) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.56M. Analysts had an estimated revenue of $4.98M. Earnings per share were $-1.19. Analysts had estimated an EPS of $-1.71.

Several Insider Transactions has been reported to the SEC. On Jan 3, 2017, Martin H. Jr. Huber (SVP & Chief Medical Officer) sold 190 shares at $136.26 per share price.Also, On Dec 14, 2016, Edward C English (VP of Finance and Admin.) sold 10,000 shares at $128.75 per share price.On Sep 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 29,166 shares at $86.04 per share price, according to the Form-4 filing with the securities and exchange commission.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.

Share this post

Leave a Reply